Ultrasonic Scientific Exhibiting at 2005 AAPS Annual Meeting and Exposition
News Oct 13, 2005
Ultrasonic Scientific Ltd has announced that it will be exhibiting its HR-US range of spectrometers at the 2005 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Nashville, Tennessee, November 6-10. Showcased on booth #2830 will be Ultrasonic Scientifics’ Colloid Stability Analyzer.
Ultrasonic claims that, the HR-US Colloid Stability Analyzer, which made its debut at PittCon 2005, is unique in the field of sedimentation and stability measurements of emulsions and suspensions; it performs non-destructive and small sample analysis and also enables the analysis of opaque materials.
As a consequence, it is an innovative instrument addressing the analytical needs of R&D and process development scientists and QA/QC analysts in the pharmaceutical, food and beverage, cosmetics, personal care and other industries.
Unlike traditional techniques, Ultrasonic Scientifics’ Colloid Stability Analyzer provides quantitative measurements, allowing accurate information to be gathered on average particle size, particle concentration and rate of sedimentation/creaming and assessing degree of flocculation/aggregation in suspensions.
The analyzer can be pressurized up to 10 bars, allowing analysis of liquids with low boiling points and liquids at high temperatures (above boiling point).
Through its HR-US series, Ultrasonic Scientific has made commercial ultrasonic instruments available for a wide spectrum of analytical tasks in a variety of industries including biotech, pharmaceutical, food, chemical and polymer.
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE
GE Focuses Portfolio for Growth and Shareholder Value CreationNews
Healthcare to become standalone company; GE expects to monetize 20% and distribute remaining 80% of GE Healthcare to shareholders tax-free.READ MORE